Skip to main content

Volume 14 Supplement 5

B cells in autoimmune diseases: Part 1

Reviews

The supplement was proposed by the journal and content was developed in consultation with the Editor-in-Chief. Articles have been independently prepared by the authors and have undergone the journal's standard peer review process. Publication of the supplement was supported by Medimmune.

This supplement has been published in two parts. Part 2 is available at http://arthritis-research.com/supplements/15/S1.

  1. Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and h...

    Authors: Henrik E Mei, Stefanie Schmidt and Thomas Dörner
    Citation: Arthritis Research & Therapy 2012 14(Suppl 5):S1

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 4.4
    5-year Journal Impact Factor: 4.9
    Source Normalized Impact per Paper (SNIP): 1.294
    SCImago Journal Rank (SJR): 1.518

    Speed 2023
    Submission to first editorial decision (median days): 9
    Submission to acceptance (median days): 111

    Usage 2023
    Downloads: 3,331,819
    Altmetric mentions: 1,885